

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 22, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933 AND
THE SECURITIES EXCHANGE ACT OF 1934**

ANI Pharmaceuticals, Inc.

**File Nos. 333-87542, 000-28637 and 001-31812
CF#32317**

ANI Pharmaceuticals, Inc. formerly BioSante Pharmaceuticals, Inc. submitted an application under Rule 406 and Rule 24b-2 requesting an extension of prior grants of confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 16, 2011, Form 10-K filed on March 27, 2007, Form SB-2 filed May 3, 2002, as amended, Form 10-KSB filed on March 28, 2002 and Form 8-K filed on July 11, 2000.

Based on representations by ANI Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit	to Form	Filed on	Confidential Treatment Granted
10.27	10-K	March 16, 2011	through March 31, 2020
10.28	10-K	March 16, 2011	through March 31, 2020
10.30	10-K	March 16, 2011	through March 31, 2020
10.31	10-K	March 16, 2011	through March 31, 2020
10.33	10-K	March 16, 2011	through March 31, 2020
10.27	10-K	March 27, 2007	through March 31, 2020
(as re-filed with fewer redactions as Exhibit 10.33 to Form 10-K filed March 16, 2011)			
10.20	SB-2	May 3, 2002	through March 31, 2020
(as re-filed with fewer redactions as Exhibit 10.31 to Form 10-K filed March 16, 2011)			
10.18	10-KSB	March 28, 2002	through March 31, 2020
(as re-filed with fewer redactions as Exhibit 10.28 to Form 10-K filed March 16, 2011)			
10.19	10-KSB	March 28, 2002	through March 31, 2020
10.20	10-KSB	March 28, 2002	through March 31, 2020
(as re-filed with fewer redactions as Exhibit 10.30 to Form 10-K filed March 16, 2011)			
10.1	8-K	July 11, 2000	through March 31, 2020
(as re-filed with fewer redactions as Exhibit 10.27 to Form 10-K filed March 16, 2011)			

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary